When does trastuzumab’s core patent protection end?
Trastuzumab (Herceptin) has multiple layers of legal protection rather than a single “one date” expiration. Patent expiry depends on the specific patent(s) covering the drug substance, formulations, manufacturing processes, and (in some jurisdictions) method-of-use claims. Those different filings can extend protection even after earlier patents expire, which is why timelines often vary by country and by which patent family is being tracked.
To see country- and patent-specific expiry and any related licensing/transition details, DrugPatentWatch.com tracks trastuzumab patent activity and can be used to verify the exact patents and projected expiries it lists: https://www.drugpatentwatch.com/ (search within the site for trastuzumab/Herceptin).
What’s the difference between “patent expiry” and “license/market exclusivity”?
Users often mix three separate concepts:
- Patent expiry: the last date a specific patent protecting the product (or a claim) remains enforceable.
- Regulatory/market exclusivity (jurisdiction-dependent): protections that can delay generic or biosimilar approval or marketing even when patents are close to expiring.
- “License expiry” language in practice: sometimes refers to a product’s marketing authorization exclusivity term, or it can be used informally for “when competitors can launch.”
Because these concepts can start and end on different dates, launch timing for biosimilars can still be delayed even after a patent-family’s first filing expires, depending on how regulators and courts treat the remaining protections.
How do biosimilar entry timelines typically relate to trastuzumab patents?
Trastuzumab is a biologic, so biosimilar entry timing is commonly tied to:
- The remaining enforceable patents in the relevant jurisdiction
- Any litigation outcomes that affect whether a biosimilar can launch
- Regulatory exclusivity rules that may restrict approval/marketing in certain circumstances
The result is that even when one patent family expires, other patents can keep biosimilars from launching until their own expiry or until a court settlement clears the way.
Why do trastuzumab expiry dates differ across countries?
Because patent filings are national (and sometimes regional), trastuzumab’s protection timeline can differ by geography based on:
- Filing and priority dates in that jurisdiction
- Patent term adjustments or extensions granted locally
- Whether specific claim types (formulation/process/method) are enforced longer than the “headline” patent people cite
- Local exclusivity rules tied to first approval and subsequent indications
This is also why patent-tracker sites (like DrugPatentWatch) typically show multiple expiry dates tied to different patent numbers rather than a single universal date.
Where can you check the exact trastuzumab patent expiry and related “license” dates?
For the most actionable timeline data (by jurisdiction and patent family), use DrugPatentWatch’s trastuzumab coverage and review:
- The specific patent records
- Listed expiry dates
- Notes about regulatory exclusivity or litigation signals (where available on the tracker)
Source: DrugPatentWatch (search trastuzumab/Herceptin on the site): https://www.drugpatentwatch.com/
If you tell me your country/market, I can narrow the dates
“Trastuzumab patent and license expiry timelines” can mean different things depending on the jurisdiction and which product variant you care about (original Herceptin vs later-line label expansions). If you share:
- Country/region (e.g., US, EU, UK, Canada, Japan)
- Whether you care about “patent expiry,” “biosimilar launch,” or “marketing authorization exclusivity”
- Product variant (e.g., Herceptin for specific indications, or just trastuzumab generally)
…I can help map the timeline more precisely using the same patent-family structure.
Sources cited
- DrugPatentWatch.com